Last reviewed · How we verify

Amzell — Portfolio Competitive Intelligence Brief

Amzell pipeline: 0 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
AMZ001 Diclofenac gel AMZ001 Diclofenac gel phase 3 Nonsteroidal anti-inflammatory drug (NSAID) COX-1 and COX-2 Pain Management / Rheumatology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Actavis Inc. · 1 shared drug class
  2. Amneal Pharmaceuticals, LLC · 1 shared drug class
  3. Assaf-Harofeh Medical Center · 1 shared drug class
  4. Azienda USL Reggio Emilia - IRCCS · 1 shared drug class
  5. Bausch & Lomb Incorporated · 1 shared drug class
  6. Bayer · 1 shared drug class
  7. Berlin-Chemie AG Menarini Group · 1 shared drug class
  8. Abbott · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Amzell:

Cite this brief

Drug Landscape (2026). Amzell — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/amzell. Accessed 2026-05-13.

Related